08:35 AM EST, 11/14/2024 (MT Newswires) -- AC Immune ( ACIU ) shares gained more than 12% in premarket trading Thursday after the company said a phase 2 clinical trial of its potential early Parkinson's disease treatment yielded "positive" interim safety and immunogenicity data

The drug candidate, ACI-7104.056, induced antibody responses against the target antigen 16 times higher than the placebo following three immunizations in the 30-patient study, the company said. It added that the treatment showed a positive safety profile.